| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/01.JCP.0000095350.32154.73 |
| P698 | PubMed publication ID | 14624186 |
| P50 | author | Blanca Gutiérrez | Q43522886 |
| P2093 | author name string | Bárbara Arias | |
| Lourdes Fañanás | |||
| Rosa Catalán | |||
| Cristóbal Gastó | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | serotonin | Q167934 |
| P304 | page(s) | 563-567 | |
| P577 | publication date | 2003-12-01 | |
| P1433 | published in | Journal of Clinical Psychopharmacology | Q6294969 |
| P1476 | title | 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study | |
| P478 | volume | 23 |
| Q48168541 | 5-HT and the brain-gut axis: opportunities for pharmacologic intervention |
| Q90727947 | 5-HTTLPR and MTHFR 677C>T polymorphisms and response to yoga-based lifestyle intervention in major depressive disorder: A randomized active-controlled trial |
| Q48868283 | A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders |
| Q42485885 | Altered response to the selective serotonin reuptake inhibitor escitalopram in mice heterozygous for the serotonin transporter: an electrophysiological and neurochemical study |
| Q58875252 | An Introduction to Pharmacogenomics and Personalized Medicine |
| Q45956855 | Analysis of association between the 5-HTTLPR and STin2 polymorphisms in the serotonin-transporter gene and clinical response to a selective serotonin reuptake inhibitor (sertraline) in patients with premature ejaculation. |
| Q34088515 | Antidepressant response and the serotonin transporter gene-linked polymorphic region |
| Q44220312 | Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder |
| Q40006472 | Association of glucocorticoid receptor polymorphisms with the susceptibility to major depressive disorder and treatment responses in Korean depressive patients |
| Q49026738 | Association of polymorphisms of the serotonergic pathways with clinical traits of impulsive-aggression and suicidality in adolescents: a multi-center study |
| Q30251779 | Associations of 5HTTLPR polymorphism with major depressive disorder and alcohol dependence: A systematic review and meta-analysis |
| Q37998561 | CB1 receptor antagonists: new discoveries leading to new perspectives |
| Q36718053 | Candidate genes for antidepressant response to selective serotonin reuptake inhibitors |
| Q37517285 | Depression and antidepressants: molecular and cellular aspects. |
| Q36493861 | Effects of genes and stress on the neurobiology of depression. |
| Q28301029 | Ethnopsychopharmacology |
| Q37692487 | Evaluation of heritable determinants of blood and brain serotonin homeostasis using recombinant inbred mice |
| Q45280761 | Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram |
| Q35012645 | Fluoxetine-induced alterations in human platelet serotonin transporter expression: serotonin transporter polymorphism effects |
| Q27015830 | From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment |
| Q36064163 | Genetic biomarkers of depression |
| Q37300029 | Genetic modulation of the serotonergic pathway: influence on weight reduction and weight maintenance |
| Q34628110 | Genetic polymorphism in the serotonin transporter gene-linked polymorphic region and response to serotonin reuptake inhibitors in patients with premature ejaculation |
| Q30485725 | How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems. |
| Q48148747 | Imaging genetics: implications for research on variable antidepressant drug response |
| Q49122438 | Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD? |
| Q48041301 | Kynurenine pathway and white matter microstructure in bipolar disorder |
| Q36675827 | Living well with stroke: design and methods for a randomized controlled trial of a psychosocial behavioral intervention for poststroke depression |
| Q36717526 | Major depression as a disorder of serotonin resistance: inference from diabetes mellitus type II. |
| Q36673952 | Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients |
| Q37198752 | Molecular epidemiology of major depressive disorder |
| Q45996939 | Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response. |
| Q46911907 | Monoaminergic function in major depression. A possibly helpful tool for choosing treatment strategy |
| Q37089315 | Neurobiological factors linking personality traits and major depression |
| Q34726454 | Personalized medicine in psychiatry: problems and promises |
| Q36904466 | Pharmacogenetic studies in depression: a proposal for methodologic guidelines |
| Q35038052 | Pharmacogenetics in drug regulation: promise, potential and pitfalls |
| Q38121519 | Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research |
| Q37989490 | Pharmacogenetics of antidepressant drugs: current clinical practice and future directions |
| Q34155796 | Pharmacogenetics of antidepressant response |
| Q37464458 | Pharmacogenetics of antidepressant response: an update |
| Q35026088 | Pharmacogenetics of antidepressants |
| Q36438205 | Pharmacogenomics and antidepressant drugs |
| Q46658086 | Polymorphism in the serotonin transporter gene and response to treatment in African American cocaine and alcohol-abusing individuals |
| Q46769754 | Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy |
| Q48588111 | Prediction of remission of depression with clinical variables, neuropsychological performance, and serotonergic/dopaminergic gene polymorphisms. |
| Q35237042 | Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder. |
| Q47666907 | Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years |
| Q37147173 | Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder |
| Q34131354 | Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice |
| Q34685706 | Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults |
| Q34871885 | Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder |
| Q48102826 | SERT and NET polymorphisms, temperament and antidepressant response |
| Q37437784 | SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. |
| Q34473840 | Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders |
| Q48048080 | Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients |
| Q35702031 | Serotonin transporter gene polymorphism and psychiatric disorders: is there a link? |
| Q34369115 | Serotonin transporter gene polymorphisms and chronic illness of depression |
| Q36491587 | Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients |
| Q51905107 | Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. |
| Q37486207 | Serotonin transporter polymorphisms, microstructural white matter abnormalities and remission of geriatric depression |
| Q33921338 | Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms. |
| Q37911004 | Surrogate markers of treatment outcome in major depressive disorder |
| Q46434375 | TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression |
| Q51846528 | The Promise and Reality of Pharmacogenetics in Psychiatry |
| Q36649081 | The interaction of serotonin transporter gene polymorphisms and early adverse life events on vulnerability for major depression |
| Q34663662 | The moderation by the serotonin transporter gene of environmental adversity in the aetiology of mental illness: review and methodological analysis |
| Q35226451 | The promise and reality of pharmacogenetics in psychiatry |
| Q47267712 | The role of genetic variability in the SLC6A4, BDNF and GABRA6 genes in anxiety-related traits. |
| Q28290605 | Treatment-resistant depression: critique of current approaches |
| Q34424865 | Understanding the pharmacogenetics of selective serotonin reuptake inhibitors |
| Q48110208 | White matter microstructure in bipolar disorder is influenced by the serotonin transporter gene polymorphism 5-HTTLPR. |
Search more.